cervarix
glaxo smith kline (israel) ltd - hpv-16 l1; hpv-18 l1 - suspension for injection - hpv-18 l1 20 mcg / 0.5 ml; hpv-16 l1 20 mcg / 0.5 ml - bacterial and viral vaccines, combined - cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant genital (cervical, vulvar and vaginal) lesions and cervical cancer causally related to certain oncogenic human papillomavirus (hpv) types.
human albumin grifols 50 g/l solution for infusion
instituto grifols s.a. - human plasma protein - solution for infusion - 50 gram(s)/litre - blood substitutes and plasma protein fractions; albumin
human albumin grifols 200g/l solution for infusion
instituto grifols s.a. - human albumin - solution for infusion - 200 gram(s)/litre - blood substitutes and plasma protein fractions; albumin
human albumin 200gl baxter
takeda pharmaceuticals (asia pacific) pte. ltd. - human albumin - solution, sterile - 200 mg/ml - human albumin 200 mg/ml
human albumin solution for infusion 20% behring
csl behring pte. ltd. - human albumin - infusion, solution - 200g/l - human albumin 200g/l
pneumovax 23 solution for injection in pre-filled syringe pneumococcal polysaccharide vaccine
merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection in pre-filled syringe - 25 mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen
pneumovax 23 solution for injection in a vial pneumococcal polysaccharide vaccine
merck sharp & dohme ireland (human health) limited - pneumococcal vaccine - solution for injection - 25mcg/0.5 millilitre(s) - pneumococcal vaccines; pneumococcus, purified polysaccharides antigen
immune serum globulin (human) solution
grifols therapeutics llc - immunoglobulin (human) - solution - 18% - immunoglobulin (human) 18% - serums
octagam immune globulin (human)- immune globulin solution
octapharma pharmazeutika produktionsgesellschaft m.b.h. - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - human immunoglobulin g 50 mg in 1 ml - octagam is an immune globulin intravenous (human) 5% liquid indicated for treatment of primary humoral immunodeficiency (pi), such as congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, wiskott-aldrich syndrome and severe combined immunodeficiencies. octagam 5% liquid is contraindicated in patients who have acute severe hypersensitivity reactions to human immunoglobulin. octagam 5% liquid contains trace amounts of iga (not more than 0.2 mg/ml in a 5% solution). it is contraindicated in iga deficient patients with antibodies against iga and history of hypersensitivity (see description [11]). octagam 5% liquid is contraindicated in patients with acute hypersensitivity reaction to corn. octagam 5% liquid contains maltose, a disaccharide sugar which is derived from corn. patients known to have corn allergies should avoid using octagam 5% liquid. pregnancy category c. animal reproduction studies have not been conducted with octagam 5% liquid. it is also not known whether o
haegarda c1 esterase inhibitor subcutaneous (human)- human c1-esterase inhibitor kit
csl behring gmbh - human c1-esterase inhibitor (unii: 6kic4bb60g) (human c1-esterase inhibitor - unii:6kic4bb60g) - human c1-esterase inhibitor 2000 [iu] in 4 ml - haegarda is a plasma-derived concentrate of c1 esterase inhibitor (human) (c1-inh) indicated for routine prophylaxis to prevent hereditary angioedema (hae) attacks in patients 6 years of age and older. haegarda is contraindicated in individuals who have experienced life-threatening hypersensitivity reactions, including anaphylaxis, to c1-inh preparations or its excipients [see description (11)]. risk summary there are no prospective clinical data from haegarda use in pregnant women. c1-inh is a normal component of human plasma. animal developmental or reproduction toxicity studies have not been conducted with haegarda. in the u.s. general population, the estimated background risk of major birth defects occurs in 2-4% of the general population and miscarriage occurs in 15-20% of clinically recognized pregnancies. data in a retrospective case collection study, 22 pregnant women with type i hae and ranging in age from 20 to 38 years received c1-inh doses of 500 or 1000 iu per i.v. administration for the treatmen